[8-K] Humacyte, Inc. Reports Material Event
Humacyte, Inc. furnished a press release reporting its financial results for the fiscal second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Current Report, but the body of the Form 8-K does not include the underlying financial figures or tables.
The filing explicitly states that the information, including the exhibit, "shall not be deemed filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference in other filings except by specific reference. The report also identifies the company as an emerging growth company and lists its securities as Common Stock (HUMA) and Redeemable Warrants (HUMAW) on Nasdaq. The filing includes Exhibit 99.1 and the Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. ha diffuso un comunicato stampa con i risultati finanziari per il secondo trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è allegato come Exhibit 99.1 ed è incorporato per riferimento nel presente Current Report, ma il corpo del Modulo 8-K non include i dati finanziari o le tabelle sottostanti.
La documentazione dichiara esplicitamente che le informazioni, incluso l'allegato, "non devono essere considerate presentate" ai fini della Sezione 18 dell'Exchange Act e non saranno incorporate per riferimento in altri depositi salvo che per specifico riferimento. Il rapporto indica inoltre la società come emerging growth company e riporta i suoi titoli come Common Stock (HUMA) e Redeemable Warrants (HUMAW) sul Nasdaq. Il deposito include l'Exhibit 99.1 e il Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. publicó un comunicado de prensa con sus resultados financieros correspondientes al segundo trimestre fiscal concluido el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en este Current Report, pero el cuerpo del Formulario 8-K no incluye las cifras financieras o las tablas subyacentes.
La presentación declara explícitamente que la información, incluido el anexo, "no se considerará presentada" a efectos de la Sección 18 del Exchange Act y no se incorporará por referencia en otros documentos salvo que se haga referencia específica. El informe también identifica a la compañía como una emerging growth company y enumera sus valores como Common Stock (HUMA) y Redeemable Warrants (HUMAW) en Nasdaq. La presentación incluye el Exhibit 99.1 y el Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc.는 회계연도 제2분기(종료일: 2025년 6월 30일)의 재무 결과를 알리는 보도자료를 발표했습니다. 보도자료는 Exhibit 99.1로 첨부되어 이 Current Report에 참조로 포함되지만, Form 8-K 본문에는 기초 재무 수치나 표가 포함되어 있지 않습니다.
해당 제출서류는 첨부문서를 포함한 정보가 Section 18 of the Exchange Act의 목적상 "제출된 것으로 간주되지 않습니다"라고 명시적으로 밝히고 있으며, 특정한 언급이 있는 경우를 제외하고는 다른 제출서류에 참조로 포함되지 않을 것이라고 명시합니다. 보고서는 또한 회사를 emerging growth company로 식별하고 있으며, 그 증권을 Nasdaq에서 Common Stock (HUMA) 및 Redeemable Warrants (HUMAW)로 기재하고 있습니다. 제출서류에는 Exhibit 99.1과 Cover Page Interactive Data File (Exhibit 104)가 포함되어 있습니다.
Humacyte, Inc. a diffusé un communiqué de presse faisant état de ses résultats financiers pour le deuxième trimestre fiscal clos le 30 juin 2025. Le communiqué est joint en tant que Exhibit 99.1 et est incorporé par renvoi dans ce Current Report, mais le corps du formulaire 8-K n'inclut pas les chiffres financiers ou les tableaux sous-jacents.
Le document précise explicitement que les informations, y compris l'annexe, "ne doivent pas être considérées comme déposées" aux fins de la Section 18 de l'Exchange Act et ne seront pas incorporées par renvoi dans d'autres dépôts sauf par référence spécifique. Le rapport identifie également la société comme une emerging growth company et indique ses titres comme Common Stock (HUMA) et Redeemable Warrants (HUMAW) sur le Nasdaq. Le dépôt comprend l'Exhibit 99.1 et le Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. hat eine Pressemitteilung mit den Finanzergebnissen für das am 30. Juni 2025 endende zweite Geschäftsquartal veröffentlicht. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird in diesen Current Report durch Verweis aufgenommen, doch der Text des Formulars 8-K enthält nicht die zugrundeliegenden Finanzkennzahlen oder Tabellen.
Die Einreichung stellt ausdrücklich fest, dass die Informationen, einschließlich des Anhangs, "nicht als eingereicht gelten" im Sinne von Section 18 des Exchange Act und nicht durch Verweis in andere Einreichungen aufgenommen werden, außer durch ausdrückliche Nennung. Der Bericht bezeichnet das Unternehmen außerdem als emerging growth company und führt seine Wertpapiere als Common Stock (HUMA) und Redeemable Warrants (HUMAW) an der Nasdaq auf. Der Einreichung sind Exhibit 99.1 und die Cover Page Interactive Data File (Exhibit 104) beigefügt.
- None.
- None.
Insights
TL;DR: Routine Form 8-K furnishing a Q2 press release; the filing itself contains no financial statements, so immediate material impact is limited.
The company used Item 2.02 to furnish its fiscal Q2 2025 press release as Exhibit 99.1 and included the Inline XBRL cover page as Exhibit 104. The filing reiterates that the furnished materials are not "filed" under Section 18, which preserves limits on incorporation by reference. For investors, the actionable financial details will appear in the attached press release rather than in this Form 8-K text.
TL;DR: Administrative disclosure consistent with standard SEC practice; the "not filed" language maintains company control over incorporation of the release.
This 8-K follows common governance practice by furnishing a press release and explicitly stating the exhibit will not be treated as "filed" under the Exchange Act. The form lists exhibits clearly (99.1 and 104) and confirms emerging growth company status. There are no governance changes, officer departures, or material agreements disclosed in this report.
Humacyte, Inc. ha diffuso un comunicato stampa con i risultati finanziari per il secondo trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è allegato come Exhibit 99.1 ed è incorporato per riferimento nel presente Current Report, ma il corpo del Modulo 8-K non include i dati finanziari o le tabelle sottostanti.
La documentazione dichiara esplicitamente che le informazioni, incluso l'allegato, "non devono essere considerate presentate" ai fini della Sezione 18 dell'Exchange Act e non saranno incorporate per riferimento in altri depositi salvo che per specifico riferimento. Il rapporto indica inoltre la società come emerging growth company e riporta i suoi titoli come Common Stock (HUMA) e Redeemable Warrants (HUMAW) sul Nasdaq. Il deposito include l'Exhibit 99.1 e il Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. publicó un comunicado de prensa con sus resultados financieros correspondientes al segundo trimestre fiscal concluido el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en este Current Report, pero el cuerpo del Formulario 8-K no incluye las cifras financieras o las tablas subyacentes.
La presentación declara explícitamente que la información, incluido el anexo, "no se considerará presentada" a efectos de la Sección 18 del Exchange Act y no se incorporará por referencia en otros documentos salvo que se haga referencia específica. El informe también identifica a la compañía como una emerging growth company y enumera sus valores como Common Stock (HUMA) y Redeemable Warrants (HUMAW) en Nasdaq. La presentación incluye el Exhibit 99.1 y el Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc.는 회계연도 제2분기(종료일: 2025년 6월 30일)의 재무 결과를 알리는 보도자료를 발표했습니다. 보도자료는 Exhibit 99.1로 첨부되어 이 Current Report에 참조로 포함되지만, Form 8-K 본문에는 기초 재무 수치나 표가 포함되어 있지 않습니다.
해당 제출서류는 첨부문서를 포함한 정보가 Section 18 of the Exchange Act의 목적상 "제출된 것으로 간주되지 않습니다"라고 명시적으로 밝히고 있으며, 특정한 언급이 있는 경우를 제외하고는 다른 제출서류에 참조로 포함되지 않을 것이라고 명시합니다. 보고서는 또한 회사를 emerging growth company로 식별하고 있으며, 그 증권을 Nasdaq에서 Common Stock (HUMA) 및 Redeemable Warrants (HUMAW)로 기재하고 있습니다. 제출서류에는 Exhibit 99.1과 Cover Page Interactive Data File (Exhibit 104)가 포함되어 있습니다.
Humacyte, Inc. a diffusé un communiqué de presse faisant état de ses résultats financiers pour le deuxième trimestre fiscal clos le 30 juin 2025. Le communiqué est joint en tant que Exhibit 99.1 et est incorporé par renvoi dans ce Current Report, mais le corps du formulaire 8-K n'inclut pas les chiffres financiers ou les tableaux sous-jacents.
Le document précise explicitement que les informations, y compris l'annexe, "ne doivent pas être considérées comme déposées" aux fins de la Section 18 de l'Exchange Act et ne seront pas incorporées par renvoi dans d'autres dépôts sauf par référence spécifique. Le rapport identifie également la société comme une emerging growth company et indique ses titres comme Common Stock (HUMA) et Redeemable Warrants (HUMAW) sur le Nasdaq. Le dépôt comprend l'Exhibit 99.1 et le Cover Page Interactive Data File (Exhibit 104).
Humacyte, Inc. hat eine Pressemitteilung mit den Finanzergebnissen für das am 30. Juni 2025 endende zweite Geschäftsquartal veröffentlicht. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird in diesen Current Report durch Verweis aufgenommen, doch der Text des Formulars 8-K enthält nicht die zugrundeliegenden Finanzkennzahlen oder Tabellen.
Die Einreichung stellt ausdrücklich fest, dass die Informationen, einschließlich des Anhangs, "nicht als eingereicht gelten" im Sinne von Section 18 des Exchange Act und nicht durch Verweis in andere Einreichungen aufgenommen werden, außer durch ausdrückliche Nennung. Der Bericht bezeichnet das Unternehmen außerdem als emerging growth company und führt seine Wertpapiere als Common Stock (HUMA) und Redeemable Warrants (HUMAW) an der Nasdaq auf. Der Einreichung sind Exhibit 99.1 und die Cover Page Interactive Data File (Exhibit 104) beigefügt.
FAQ
What did Humacyte (HUMA) disclose in this Form 8-K?
Is the press release included in the filing considered "filed" with the SEC?
Which exhibits were attached to the Humacyte 8-K?
Does this 8-K include financial statements or tables for Q2 2025?
What securities of Humacyte are listed and on which exchange?
